G단백질 결합 수용체 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 검정별, 지역별, 부문 예측(2025-2030년)

G-Protein Coupled Receptors Market Growth & Trends:

The global G-protein coupled receptors market size is expected to reach USD 5.55 billion by 2030 registering a CAGR of 6.10% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising adoption of faster and accurate High-Throughput Screening (HTS) technology by pharmaceutical firms to develop potential G-protein coupled receptor(GPCR)-targeted therapeutics is expected to augment the market growth. HTS is used on the G-protein coupled receptor cell-based assays to assist several drug development programs.

Structural and functional features of G-protein coupled receptors (GPCRs) allow it to mediate physiological responses to hormones, stimulants, and neurotransmitters, thus making them as potential therapeutic targets for various diseases. Recent advancements in the structural biology of GPCRs have provided insights into the molecular mechanisms of these receptors' activation and activity. Several pharmaceutical companies are undertaking efforts to develop G-protein coupled receptors-targeted therapeutics for several disorders.

In December 2018, Boehringer Ingelheim collaborated with Domain Therapeutics to discover GPCR targets for the treatment of cancer, Central Nervous System (CNS), and immunological disorders. Moreover, in May 2019, Evotec OAI AG partnered with Euroscreen S.A. to improve its capabilities for GPCR targeting. Evotec OAI will access GPCR reagents and AequoScreenTM technology of Euroscreen for its drug discovery procedures. Such initiatives enhance the product adoption as well as drug screening expertise in the pharmaceutical industry.

North America is likely to be at the forefront of the market throughout the forecast period due to heavy investments in cancer research to address the rising demand for drug discovery and development procedures in U.S. Whereas, Asia Pacific is expected to register the fastest CAGR over the forecast years. The region witnesses a rising number of therapeutics development and contract research, thus boosting G-protein coupled receptors market growth.

G-Protein Coupled Receptors Market Report Highlights:

• Based on products, the cell lines segment dominated the market with the largest revenue share in 2022, owing to the availability of an extensive range of cell lines for the assays.
• The cAMP functional assays segment dominated the market with the largest revenue share of 32.5% in 2024 because cyclic Adenosine Monophosphate is an important intracellular second messenger in GPCR signal transduction.
• The cancer research segment dominated the market, with the largest revenue share of 31.5% in 2024. Many applications are associated with G-protein-coupled receptor activity for treating several disorders.
• North America G-Protein coupled receptors industry dominated globally with the largest revenue share of 36.9% in 2024 due to strategic investments in cancer research, approval of GPCR-targeted drugs, and increased focus on drug discovery & development activities.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Assay
  • 1.1.3. Application
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. G-protein Coupled Receptors Market Variables and Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. G-protein Coupled Receptors: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. G-protein Coupled Receptors Market: Product Movement Analysis
• 4.3. G-protein Coupled Receptors Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Cell lines
  • 4.4.1. Cell lines market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Detection kits
  • 4.5.1. Detection kits market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Cell Culture Reagents
  • 4.6.1. Cell culture reagents market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Ligands
  • 4.7.1. Ligands market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. G-protein Coupled Receptors: Assay Estimates & Trend Analysis

• 5.1. Assay Segment Dashboard
• 5.2. G-protein Coupled Receptors Market: Assay Movement Analysis
• 5.3. G-protein Coupled Receptors Market Size & Trend Analysis, by Assay, 2018 to 2030 (USD Million)
• 5.4. cAMP Functional Assays
  • 5.4.1. cAMP functional assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Calcium Functional Assays
  • 5.5.1. Calcium functional assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. B-Arrestin Functional Assays
  • 5.6.1. B-Arrestin functional assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Radioligand Binding and GTPYS Functional Assays
  • 5.7.1. Radioligand binding and GTPYS functional assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Internationalization Assays
  • 5.8.1. Internationalization assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Trafficking Assays
  • 5.9.1. Trafficking assays market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Other Assays
  • 5.10.1. Other assays market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. G-protein Coupled Receptors: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. G-protein Coupled Receptors Market: Application Movement Analysis
• 6.3. G-protein Coupled Receptors Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Cancer Research
  • 6.4.1. Cancer research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. CNS Research
  • 6.5.1. CNS research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Metabolic Research
  • 6.6.1. Metabolic research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Cardiovascular Research
  • 6.7.1. Cardiovascular research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Inflammation Research
  • 6.8.1. Inflammation research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Respiratory Research
  • 6.9.1. Respiratory research market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.10. Other Applications
  • 6.10.1. Other applications market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. G-protein Coupled Receptors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. G-protein Coupled Receptors Market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.7. South Korea
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.3. South Africa
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Participant Overview
  • 8.3.1. Thermo Fisher Scientific Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Eurofins Scientific
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. QIAGEN
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. WuXi AppTec
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Promega Corporation
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Abcam plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Merck KGaA
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. PerkinElmer Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Enzo Biochem Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. BD
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives